Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

Expert Review of Hematology
Hsin-An Hou, Hwei-Fang Tien

Abstract

Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogenetics. Here we describe the clinic-biologic features of AML patients with these mutations, their prognostic relevance and potential as therapeutic targets. The epigenetic alterations are present as the early pre-leukemic events and usually remain stable during disease evolution, implying the potential to be biomarkers for minimal residual disease monitoring. The high frequency of mutations in epigenetic modifiers and their prognostic implications shed light on the development of epigenetic therapy.

References

Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Dec 24, 2002·Nature Immunology·I-Hsin SuAlexander Tarakhovsky
Oct 3, 2003·Cancer Cell·Mary Ellen MartinJay L Hess
Apr 27, 2005·Cell·Yuki OkadaYi Zhang
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingeborg M BachmannLars A Akslen
May 27, 2006·Nature·Pedro V PeñaTatiana G Kutateladze
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanUNKNOWN Cancer and Leukemia Group B
Sep 13, 2006·British Journal of Haematology·Jorg BaseckeFred E Bertrand
Sep 19, 2006·The Journal of Clinical Investigation·Adrienne M DorranceMichael A Caligiuri
Oct 13, 2006·Molecular and Cellular Biology·Christopher R VakocGerd A Blobel
Oct 17, 2007·Annual Review of Medicine·Einav Nili Gal-YamPeter A Jones
Oct 25, 2007·Nature Reviews. Cancer·Andrei V Krivtsov, Scott A Armstrong
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Apr 25, 2009·British Journal of Haematology·Véronique Gelsi-BoyerDaniel Birnbaum
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Jun 2, 2009·Nature Genetics·Saskia M C LangemeijerJoop H Jansen
Jun 19, 2009·Haematologica·Robert K Slany
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.